Kava--the unfolding story: report on a work-in-progress

Area of Science:

• Pharmacovigilance
• Herbal Medicine Safety
• Regulatory Science

Background:

• A German report (BfArM) in late 2001 detailed adverse events linked to concentrated kava (Piper methysticum) preparations.
• Analysis revealed duplications in the cited BfArM case reports, prompting a review by UK authorities (CSM).
• Worldwide evaluation of kava safety is ongoing, impacting public health, regulatory bodies, and kava producers.

Purpose of the Study:

• To analyze the BfArM report on kava adverse events and address the kava safety controversy.
• To differentiate between adverse events caused by concentrated kava extracts and traditional preparations.
• To propose measures for ensuring the continued availability of safe kava preparations in the UK.

Main Methods:

• Review and analysis of adverse event reports compiled by the German Federal Institute for Drugs and Medical Products (BfArM).
• Comparison of case reports to identify duplications and assess the validity of cited adverse events.
• Formulation of recommendations based on the analysis of kava preparation types and reported safety data.

Main Results:

• The BfArM report contained duplications, suggesting potential overestimation of adverse events.
• Many cited adverse events may not be attributable to kava itself.
• Concentrated, standardized kava extracts appear more likely to be associated with adverse events than traditional preparations.

Conclusions:

• The safety evaluation of kava requires careful consideration of preparation methods.
• Concentrated kava extracts warrant further investigation regarding their adverse event profile.
• Implementing specific measures can facilitate the safe use of traditional kava preparations.